View Clinical Trial (Medical Research Study)
Immunolabeling Evaluation of Five Selected Markers in Skin Biopsies of Patients With Postherpetic Neuralgia (PHN) and Age and Gender-Matched Normal Controls
| City: |
|
Albany |
| State: |
|
New York |
| Zip Code: |
|
12208 |
| Conditions: |
|
Postherpetic Neuralgia - Healthy Age/Gender Matched Volunteers |
| Purpose: |
|
Postherpetic Neuralgia is a painful nerve condition that can occur when nerve fibers are
damaged following an outbreak of shingles.
The purpose of this study is to identify and study abnormalities in the nerves and cells in
the of patients with postherpetic Neuralgia (PHN) and characterize changes that could be
responsible for causing nerve pain. This data will be compared to the tissue of healthy
volunteers. Our goal is that this information will lead to the development of better
treatment options for people with painful nerve conditions.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
Group 1: 5 Caucasian males >50 years of age with PHN of greater than 6 months duration
since rash healed and clinically meaningful pain (Visual Analog Scale (VAS) >40mm at
Baseline) Group 2: 5 Caucasian males >50 years of age, non-diabetic with no nervous system
disease (healthy control groups)
Exclusion Criteria:
1. History of clinically significant liver disease, serious peripheral vascular disease,
a blood clotting disorder, or any other medical condition felt to be exclusionary by
the investigator
2. Allergy to lidocaine
3. Unwillingness to sign informed consent or any other reasons for which the
investigator feels the subject cannot complete the study
4. History of slow-healing diabetic foot ulcers
5. HgA1c >11% within the last three months
6. Active cancer within the previous two years, except treated basal cell carcinoma of
the skin
7. Co-morbidities that can produce neuropathy
8. Subjects taking sodium channel blockers within one week of study treatment and
throughout the study
9. Subjects taking any other experimental drugs within 30 days prior to enrollment
10. Application of lidocaine patch to either foot or to PHN site within two weeks of
enrollment
|
| NCT ID: |
|
NCT01379716 |
| Primary Contact: |
|
Principal Investigator
James P. Wymer, MD
Albany Medical College
Margaret Czerwinski, BSN, RN
Phone: (518)262-0034
Email: czerwim@mail.amc.edu
|
| Backup Contact: |
|
Email: regank@mail.amc.edu
Katy Regan, BS
Phone: (518)262-5938
|
| Location Contact: |
|
Albany, New York 12208
United States
There is no listed contact information for this specific location.
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 21, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|